How to buy Jazz Pharmaceuticals stock (JAZZ)

Jazz Pharmaceuticals is a biotechnology business based in the US. Jazz Pharmaceuticals shares (JAZZ) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $122.85 – a decrease of 0.15% over the previous week. Jazz Pharmaceuticals employs 2,800 staff and has a trailing 12-month revenue of around $4 billion.

Our top picks for where to buy Jazz Pharmaceuticals stock

Buy Jazz Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Jazz Pharmaceuticals stock price (NASDAQ: JAZZ)

Use our graph to track the performance of JAZZ stocks over time.

Jazz Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$122.85
52-week range	$99.06 - $134.17
50-day moving average more info button	$117.72
200-day moving average more info button	$112.64
Wall St. target price	$181.05
PE ratio more info button	17.2436
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$7.06

Is it a good time to buy Jazz Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Jazz Pharmaceuticals price performance over time

Historical closes compared with the close of $121.74 from 2024-12-18

1 week (2024-12-13)	-1.06%
1 month (2024-11-20)	2.10%
3 months (2024-09-20)	9.91%
6 months (2024-06-20)	13.39%

1 year (2023-12-20)	1.69%
2 years (2022-12-20)	-21.98%
3 years (2021-12-20)	126.5
5 years (2019-12-20)	153.25

Is Jazz Pharmaceuticals stock undervalued or overvalued?

Valuing Jazz Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jazz Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Jazz Pharmaceuticals's P/E ratio

Jazz Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Jazz Pharmaceuticals shares trade at around 17x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Jazz Pharmaceuticals's PEG ratio

Jazz Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8364. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Jazz Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Jazz Pharmaceuticals's EBITDA

Jazz Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.5 billion.

The EBITDA is a measure of a Jazz Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Jazz Pharmaceuticals financials

Revenue TTM	$4 billion
Operating margin TTM	24.67%
Gross profit TTM	$3.4 billion
Return on assets TTM	4.62%
Return on equity TTM	12.09%
Profit margin	11.6%
Book value	$69.01
Market Capitalization more info button	$7.4 billion

TTM: trailing 12 months

Jazz Pharmaceuticals share dividends

We're not expecting Jazz Pharmaceuticals to pay a dividend over the next 12 months.

Jazz Pharmaceuticals share price volatility

Over the last 12 months, Jazz Pharmaceuticals's shares have ranged in value from as little as $99.06 up to $134.17. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jazz Pharmaceuticals's is 0.573. This would suggest that Jazz Pharmaceuticals's shares are less volatile than average (for this exchange).

Jazz Pharmaceuticals overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. .

Frequently asked questions

What percentage of Jazz Pharmaceuticals is owned by insiders or institutions?
Currently 2.935% of Jazz Pharmaceuticals shares are held by insiders and 98.642% by institutions. How many people work for Jazz Pharmaceuticals?
Latest data suggests 2,800 work at Jazz Pharmaceuticals. When does the fiscal year end for Jazz Pharmaceuticals?
Jazz Pharmaceuticals's fiscal year ends in December. Where is Jazz Pharmaceuticals based?
Jazz Pharmaceuticals's address is: Waterloo Exchange, Dublin, Ireland, D04 E5W7 What is Jazz Pharmaceuticals's ISIN number?
Jazz Pharmaceuticals's international securities identification number is: USG508711052 What is Jazz Pharmaceuticals's CUSIP number?
Jazz Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 472147107